An overview of developing TNF-α targeted therapy for the treatment of psoriasis

Expert Opinion on Investigational Drugs

Volumn 24, Issue 10, 2015, Pages 1343-1354

  Campa, Molly ^a   Ryan, Caitriona ^a   Menter, Alan ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

anti TNF agents; biosimilar therapies; curcumin; psoriasis; psoriatic arthritis; targeted therapies

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CURCUMIN; ETANERCEPT; HYBRID PROTEIN; INFLIXIMAB; NARINGENIN; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR HYFC FUSION PROTEIN; UNCLASSIFIED DRUG; VACCINE; ANTIINFLAMMATORY AGENT; BIOSIMILAR AGENT; DERMATOLOGICAL AGENT; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PSORIASIS; PSORIASIS VULGARIS; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOSIMILAR PHARMACEUTICALS; DERMATOLOGIC AGENTS; DRUG DESIGN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR TARGETED THERAPY; PSORIASIS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84941600025     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1076793     Document Type: Review

References (112)

1. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999; 20 (1): 40-6
2. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26 (4): 314-20
3. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361 (5): 496-509
4. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58 (5): 826-50
5. Nograles KE, Krueger JG. Anti-cytokine therapies for psoriasis. Exp Cell Res 2011; 317 (9): 1293-300
6. Amatya B, Wennersten G, Nordlind K. Patients perspective of pruritus in chronic plaque psoriasis: a questionnaire-based study. J Eur Acad Dermatol Venereol 2008; 22 (7): 822-6
7. Armstrong AW, Schupp C, Wu J, et al. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS One 2012; 7 (12): e52935
8. Kupetsky EA, Mathers AR, Ferris LK. Anti-cytokine therapy in the treatment of psoriasis. Cytokine 2013; 61 (3): 704-12
9. Pariser DM, Bagel J, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol 2007; 143 (2): 239-42
10. Mee JB, Johnson CM, Morar N, et al. The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasis. Am J Pathol 2007; 171 (1): 32-42
11. Sa SM, Valdez PA, Wu J, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007; 178 (4): 2229-40
12. Fantuzzi F, Del Giglio M, Gisondi P, et al. Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. Expert Opin Ther Targets 2008; 12 (9): 1085-96
13. Kimber I, Cumberbatch M, Dearman RJ, et al. Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization. Br J Dermatol 2000; 142 (3): 401-12
14. Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunology (Baltimore, MD: 1950) 2005; 175 (4): 2721-9
15. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51 (4): 534-42
16. Chomarat P, Dantin C, Bennett L, et al. TNF skews monocyte differentiation from macrophages to dendritic cells. J Immunol (Baltimore, Md: 1950) 2003; 171 (5): 2262-9
17. Bradley JR. TNF-mediated inflammatory disease. J Pathol 2008; 214 (2): 149-60
18. Ottaviani C, Nasorri F, Bedini C, et al. CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol 2006; 36 (1): 118-28
19. Ihnatko R, Kubes M. TNF signaling: early events and phosphorylation. Gen Physiol Biophys 2007; 26 (3): 159-67
20. Aggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol 2013; 169 (8): 1672-92
21. Zalevsky J, Secher T, Ezhevsky SA, et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol (Baltimore, MD: 1950). 2007; 179 (3): 1872-83
22. Ettehadi P, Greaves MW, Wallach D, et al. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96 (1): 146-51
23. Gisondi P, Gubinelli E, Cocuroccia B, et al. Targeting tumor necrosis factor-alpha in the therapy of psoriasis. Curr Drug Targets Inflamm Allergy 2004; 3 (2): 175-83
24. Blackstone EA, Fuhr JP Jr. Innovation and Competition: Will Biosimilars Succeed?: The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety. Biotechnol Healthc 2012; 9 (1): 24-7
25. Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits 2013; 6 (8): 469-78
26. Gahoual R, Biacchi M, Chicher J, et al. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry. mAbs 2014; 6 (6): 1464-73
27. Strober BE, Armour K, Romiti R, et al. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol 2012; 66 (2): 317-22
28. Weise M, Kurki P, Wolff-Holz E, et al. Biosimilars: the science of extrapolation. Blood 2014; 124 (22): 3191-6
29. Mysler E. Biosimilars: clinical interpretation and implications for drug development. Curr Rheumatol Rep 2015; 17 (2): 8
30. McCamish M, Woollett G. Worldwide experience with biosimilar development. mAbs 2011; 3 (2): 209-17
31. Gomollon F. Biosimilars: are they bioequivalent? Dig Dis (Basel, Switzerland) 2014; 32 (Suppl 1): 82-7
32. Cimzia® (certolizumab pegol) [prescribing information]. UCB, Brussels, Belgium, 2008. Available from: http://cimzia.com/assets/pdf/Prescribing-Information.pdf
33. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohns disease. N Eng J Med 2007; 357 (3): 228-38
34. Keystone E, Heijde D, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008; 58 (11): 3319-29
35. Ortonne J SW TC, Reich K. Safety and efficacy of subcutaneous certolizumab pegol, a new TNF-alpha monoclonal antibody, in patients with moderate-to-severe chronic plaque psoriasis: preliminary results from a double-blind, placebo-controlled trial. Annual Meeting of the American Academy of Dermatology. Washington, DC, 2007
36. Simponi® (golimumab) [prescribing information]. Janssen Biotech, Beerse, Belgium, 2009. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/125289s0064lbl.pdf. [Last accessed 18 July 2015]
37. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366 (9494): 1367-74
38. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367 (9504): 29-35
39. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56 (1): 31-e1-15
40. Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012; 71 (3): 319-26
41. Humira™ (adalimumab) [prescribing information]. AbbVie, North Chicago, IL, 2003. Available from: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930B1-02-B-Abbott-Humira%20Prescribing%20Info.pdf. [Last accessed 30 May 2015]
42. Lis K, Kuzawinska O, Balkowiec-Iskra E. Tumor necrosis factor inhibitors-state of knowledge. Arch Med Sci 2014; 10 (6): 1175-85
43. Remicade® (infliximab) [prescribing information]. Janssen Biotech, Beerse, Belgium, 1998. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/103772s5359lbl.pdf. [Last accessed 30 March 2015]
44. Enbrel ® (etanercept) [prescribing information]. Amgen, Thousand Oaks, CA, 2003. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2003/etanimm060503LB.pdf. [Last accessed 30 March 2015]
45. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Eng J Med 2003; 349 (21): 2014-22
46. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55 (4): 598-606
47. Lynch M, Kirby B, Warren RB. Treating moderate to severe psoriasis-best use of biologics. Expert Rev Clin Immunol 2014; 10 (2): 269-79
48. Cheng J, Feldman SR. The cost of biologics for psoriasis is increasing. Drugs Context 2014; 3: 212266
49. Atzeni F, Gianturco L, Talotta R, et al. Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern? Immunotherapy 2015; 7 (4): 353-61
50. Tsiftsoglou AS, Ruiz S, Schneider CK. Development and regulation of biosimilars: current status and future challenges. BioDrugs 2013; 27 (3): 203-11
51. Li EC, Abbas R, Jacobs IA, et al. Considerations in the early development of biosimilar products. Drug Discov Today 2015; 20 (Suppl 2): 1-9
52. USFDA. Biosimilars: Questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.pdf. [Last accessed 30 May 2015]
53. Challand R, Gorham H, Constant J. Biosimilars: where we were and where we are. J Biopharm Stat 2014; 24 (6): 1154-64
54. USFDA. Scientific considerations in demonstrating biosimilarity to a reference product. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
55. AbbVie. AbbVie receives orphan drug status for Humira® (adalimumab) from the U.S. Food and Drug Administration for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS). PRNewswire 2015
56. Feagan BG, Choquette D, Ghosh S, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 2014; 42 (4): 177-83
57. Clinical Trial NCT02451839. Available from: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02451839. [Last accessed 1 June 2015]
58. Clinical Trial NCT02395055. Available from: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02395055. [Last accessed 1 June 2015]
59. Clinical Trial ISRCTN70649397. Available from: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN70649397. [Last accessed 1 June 2015]
60. Clinical Trial CTRI/2015/02/005524. Available from: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2015/02/005524. [Last accessed 1 June 2015]
61. Clinical Trial NCT02237729. Available from: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02237729. [Last accessed 1 June 2015]
62. Clinical Trial NCT02260791. Available from: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02260791. [Last accessed 1 June 2015]
63. Clinical Trial NCT02167139. Available from: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02167139. [Last accessed 1 June 2015]
64. Clinical Trial CTRI/2014/04/004571. Available from: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2014/04/004571. [Last accessed 1 June 2015]
65. Clinical Trial EUCTR2012-002945-40-DE. Available from: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012-002945-40-DE. [Last accessed 1 June 2015]
66. Clinical Trial CTRI/2013/10/004040. Available from: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2013/10/004040. [Last accessed 1 June 2015]
67. Clinical Trial NCT02346240. Available from: https://clinicaltrials.gov/ct2/show/NCT02346240. [Last accessed 10 May 2015]
68. Clinical Trial NCT02326298. Available from: https://clinicaltrials.gov/ct2/show/NCT02326298. [Last accessed 11 May 2015]
69. Clinical Trial NCT02326272. Available from: https://clinicaltrials.gov/ct2/show/NCT02326272. [Last accessed 11 May 2015]
70. Clinical Trial NCT02019602. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02019602. [Last accessed 11 May 2015]
71. Clinical Trial NCT02154425. Available from: https://clinicaltrials.gov/ct2/show/NCT02154425. [Last accessed 11 May 2015]
72. Bae YS, Van Voorhees AS, Hsu S, et al. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2012; 67 (3): 459-77
73. Jung K, Lee D, Lim HS, et al. Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis. J Bio Chem 2011; 286 (16): 14410-18
74. Furrer E, Berdugo M, Stella C, et al. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci 2009; 50 (2): 771-8
75. Ottiger M, Thiel MA, Feige U, et al. Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest Ophthalmol Vis Sci 2009; 50 (2): 779-86
76. Furrer E, Hulmann V, Urech DM. Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain. J Neuroimmunol 2009; 215 (1-2): 65-72
77. Tsianakas A GK, Berger C, et al. Topical administration of the single-chain anti-TNF-alpha antibody DLX105 suppresses TNF-alpha and Th17 cytokines in psoriatic skin. 44th Annual ESDR Meeting. Copenhagen, Denmark, 2014
78. Lou J. S3Bio, Inc., Investor Presentation. 30th Annual JP Morgan Healthcare Conference; 9-12 January 2012, San Francisco, CA
79. 3SBio. Available from: www.3sbio.com/en/innovation/other-areas/anti-tnf. [Last accessed 12 July 2015]
80. In Conversation with David Giljohann. Available from: http://biotuesdays.com/2015/02/10/in-conversation-with-david-giljohann. [Last accessed 5 May 2015]
81. Aurasense Therapeutics Pipeline. Available from: http://www.aurasensetherapeutics.com/pipeline.aspx. [Last accessed 7 May 2015]
82. DE S. XPro™ 1595, A dominant negative biologic that selectively inhibits soluble TNF. Available from: http://www.xencor.com/wp-content/uploads/2011/03/acr-2007-1595.pdf. [Last accessed 6 May 2015]
83. Steed PM, Tansey MG, Zalevsky J, et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 2003; 301 (5641): 1895-8
84. Perrier C, de Hertogh G, Cremer J, et al. Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis. Inflamm Bowel Dis 2013; 19 (2): 246-53
85. Xpro 1595. Available from: http://fprtbio.dreamhosters.com/products/. [Last accessed 15 July 2015]
86. Protalix Pipeline. Available from: http://www.protalix.com/development-pipeline/prx-106-autoimmune.asp. [Last accessed 6 May 2015]
87. Shaaltiel Y, et al. A novel method for anti-TNF based-oral immunotherapy: Oral administration of a plant cell-expressed recombinant anti-TNF fusion protein for treating of Crohns disease. Digestive Disease Week Annual Meeting. Chicago, Illinois, 2014
88. Delenex Pipeline. Available from: http://www.delenex.ch/en/Pipeline/Introduction.php. [Last accessed 2015 May 5]
89. Clinical Trial NCT02243787. Available from: https://clinicaltrials.gov/ct2/show/NCT02243787. [Last accessed 29 March 2015]
90. Mansikka HRM, Hugunin M, Ivanov A, et al. Safety, tolerability, and functional activity of ABT-122, a dual TNF- and IL-17A-targeted DVD-Ig™, following single-dose administration in healthy subjects. American College of Rheumatology 2014 Annual Meeting. Boston, Massachusetts, 2014
91. Clinical Trial NCT02349451. Available from: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02349451. [Last accessed 1 June 2015]
92. Clinical Trial NCT01899755. Available from: https://clinicaltrials.gov/ct2/show/NCT01899755. [Last accessed 16 April 2015]
93. Genexine hyFc. Available from: http://www.genexine.com/sub0301. [Last accessed 6 May 2015]
94. Lee JH, Cho JH, Yeo J, et al. The pharmacology study of a new recombinant TNF receptor-hyFc fusion protein. Biologicals 2013; 41 (2): 77-83
95. He MM, Smith AS, Oslob JD, et al. Small-molecule inhibition of TNF-alpha. Science 2005; 310 (5750): 1022-5
96. Luzi S, Kondo Y, Bernard E, et al. Subunit disassembly and inhibition of TNFalpha by a semi-synthetic bicyclic peptide. Protein Eng Des Sel 2015; 28 (2): 45-52
97. Keerthy HK, Mohan CD, Sivaraman Siveen K, et al. Novel synthetic biscoumarins target tumor necrosis factor-alpha in hepatocellular carcinoma in vitro and in vivo. J Bio Chem 2014; 289 (46): 31879-90
98. Rangappa K. Development of small molecule targeting TNF-alpha, STAT3, and NF-kB in hepatocellular carcinoma. International Conference and Expo on Drug Discovery and Designing; Frankfurt, Germany: 2015
99. Ma L, Gong H, Zhu H, et al. A novel small-molecule tumor necrosis factor alpha inhibitor attenuates inflammation in a hepatitis mouse model. J Bio Chem 2014; 289 (18): 12457-66
100. Spohn G, Guler R, Johansen P, et al. A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol (Baltimore, MD: 1950) 2007; 178 (11): 7450-7
101. Leo 32731. Available from: http://www.hra.nhs.uk/news/research-summaries/leo-32731-sadmad-study/. [Last accessed 29 March 2015]
102. Carter PH, Scherle PA, Muckelbauer JK, et al. Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha. Proc Natl Acad Sci USA 2001; 98 (21): 11879-84
103. Nguyen TA, Friedman AJ. Curcumin: a novel treatment for skin-related disorders. J Drugs Dermatol 2013; 12 (10): 1131-7
104. Shishodia S. Molecular mechanisms of curcumin action: gene expression. BioFactors (Oxford, England) 2013; 39 (1): 37-55
105. Kurd SK, Smith N, VanVoorhees A, et al. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial. J Am Acad Dermatol 2008; 58 (4): 625-31
106. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 2013; 15 (1): 195-218
107. Gupta SC, Kismali G, Aggarwal BB. Curcumin, a component of turmeric: from farm to pharmacy. BioFactors (Oxford, England) 2013; 39 (1): 2-13
108. Clinical Trial NCT02251678. Available from: https://clinicaltrials.gov/ct2/show/NCT02251678. [Last accessed 2 May 2015]
109. Gaggeri R, Rossi D, Christodoulou MS, et al. Chiral flavanones from Amygdalus lycioides Spach: structural elucidation and identification of TNFalpha inhibitors by bioactivity-guided fractionation. Molecules (Basel, Switzerland) 2012; 17 (2): 1665-74
110. Gaggeri R, Rossi D, Daglia M, et al. An eco-friendly enantioselective access to (R)-naringenin as inhibitor of proinflammatory cytokine release. Chem Biodiv 2013; 10 (8): 1531-8
111. Chlapanidas T, Perteghella S, Leoni F, et al. TNF-alpha blocker effect of naringenin-loaded sericin microparticles that are potentially useful in the treatment of psoriasis. Int J Mol Sci 2014; 15 (8): 13624-36
112. FDA Statement on the voluntary withdrawal of Raptiva from the US market. 2009. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149561.htm